ContributorsPublishersAdvertisers

#Biontech

Chinese mRNA COVID vaccine gets 1st ever approval, in Indonesia

A Chinese mRNA COVID vaccine received its first emergency use authorization in Indonesia for people aged 18 years and above, even before approval in its home country China, Reuters reported. Indonesia's food and drug authority (BPOM) granted emergency use authorization to the mRNA COVID vaccine called AWcorna, developed by Walvax...
WORLD
Picture for Chinese mRNA COVID vaccine gets 1st ever approval, in Indonesia
Nature.com

The Clinical Pipeline - a new column from Nature Medicine

This week Nature Medicine published the third in a new fortnightly column called The Clinical Pipeline. Our goal is to further strengthen the journal's coverage of translational and clinical research, from bench to bedside, and so each column will analyse a recent clinical trial announcement, preprint, or journal publication (with all the caveats that apply to non-peer reviewed research!)
MEDICAL & BIOTECH
Picture for The Clinical Pipeline - a new column from Nature Medicine

Weak demand for bivalent COVID boosters in Florida

Floridians aren't rushing to get the updated COVID-19 boosters that were distributed statewide this month. What's happening: A state health report released Friday shows that only 37,000 of Florida's 20 million eligible residents received the new bivalent vaccine, which is intended to target Omicron subvariants, the South Florida Sun-Sentinel reports.
FLORIDA STATE
Picture for Weak demand for bivalent COVID boosters in Florida
tipranks.com

BioNTech, Pfizer complete submission to EMA for bivalent booster for ages 5-11

Pfizer (PFE) and BioNTech SE (BNTX) announced they have completed a submission to the European Medicines Agency, or EMA, for a 10-microgram booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children 5 through 11 years of age. "This application for a variation of the marketing authorization to include the Omicron BA.4/BA.5-adapted bivalent vaccine in this age group is supported by safety and immunogenicity data from the companies’ Omicron BA.1-adapted bivalent vaccine, non-clinical and manufacturing data from the companies’ 10-microgram Omicron BA.4/BA.5-adapted bivalent vaccine, and preclinical data from the companies’ Omicron BA.4/BA.5-adapted bivalent vaccine," the companies stated. Reference Link.
MEDICAL & BIOTECH
americanbankingnews.com

Short Interest in BioNTech SE (NASDAQ:BNTX) Expands By 56.5%

Several hedge funds have recently modified their holdings of the business. Invesco Ltd. increased its position in BioNTech by 820.6% during the fourth quarter. Invesco Ltd. now owns 69,212 shares of the company’s stock valued at $17,843,000 after acquiring an additional 61,694 shares during the last quarter. Rockefeller Capital Management L.P. increased its position in BioNTech by 367.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 4,980 shares of the company’s stock valued at $1,283,000 after acquiring an additional 3,915 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in BioNTech during the fourth quarter valued at $316,000. Guggenheim Capital LLC increased its position in BioNTech by 42.8% during the fourth quarter. Guggenheim Capital LLC now owns 21,015 shares of the company’s stock valued at $5,418,000 after acquiring an additional 6,294 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in BioNTech during the fourth quarter valued at $22,867,000. Hedge funds and other institutional investors own 13.77% of the company’s stock.
STOCKS
MySanAntonio

Merck in deal with Sinopharm to bring Covid antiviral to China

Merck & Co. struck a deal with Chinese state-owned drugmaker Sinopharm to import and market its antiviral molnupiravir in China, in a tentative sign the country is considering more Covid-19 medicines from overseas developers. Merck and Sinopharm are also evaluating the feasibility of a technological transfer that will facilitate the...
HEALTH
YOU MAY ALSO LIKE